Makena by the numbers
Even with the price
reduction it announced last Friday, KV Pharmaceutical Co. is asking the
U.S. healthcare system, including cash-strapped Medicaid programs, to pay a
substantial premium for an FDA-approved version of hydroxyprogesterone caproate
compared with products available from compounding pharmacies.